[go: up one dir, main page]

EA201000903A1 - Антитела к pcrv-антигену pseudomonas aeruginosa - Google Patents

Антитела к pcrv-антигену pseudomonas aeruginosa

Info

Publication number
EA201000903A1
EA201000903A1 EA201000903A EA201000903A EA201000903A1 EA 201000903 A1 EA201000903 A1 EA 201000903A1 EA 201000903 A EA201000903 A EA 201000903A EA 201000903 A EA201000903 A EA 201000903A EA 201000903 A1 EA201000903 A1 EA 201000903A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pseudomonas aeruginosa
pcrv
antitel
antigen
administered
Prior art date
Application number
EA201000903A
Other languages
English (en)
Inventor
Кристофер Р. Реббингтон
Кеннет Люрсен
Джеффри Т. Яррантон
Марк Баер
Original Assignee
Калобиос Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калобиос Фармасьютикалс, Инк. filed Critical Калобиос Фармасьютикалс, Инк.
Publication of EA201000903A1 publication Critical patent/EA201000903A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение обеспечивает высокоаффинные антитела к белку PcrV Pseudomonas aeruginosa, которые обладают пониженной иммуногенностью при введении для лечения вызванных Pseudomonas aeruginosa инфекций.
EA201000903A 2007-11-30 2008-12-01 Антитела к pcrv-антигену pseudomonas aeruginosa EA201000903A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
EA201000903A1 true EA201000903A1 (ru) 2011-02-28

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000903A EA201000903A1 (ru) 2007-11-30 2008-12-01 Антитела к pcrv-антигену pseudomonas aeruginosa

Country Status (15)

Country Link
US (3) US8044181B2 (ru)
EP (1) EP2220117A2 (ru)
JP (1) JP5781765B2 (ru)
KR (1) KR20100097719A (ru)
CN (1) CN101910197B (ru)
AU (1) AU2008333985B2 (ru)
BR (1) BRPI0819598A2 (ru)
CA (1) CA2706732A1 (ru)
EA (1) EA201000903A1 (ru)
IL (1) IL206036A0 (ru)
MX (1) MX2010005871A (ru)
NZ (1) NZ586357A (ru)
SG (1) SG186017A1 (ru)
WO (1) WO2009073631A2 (ru)
ZA (1) ZA201003852B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2685326A1 (en) * 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009088032A1 (ja) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. ＰｃｒＶに対する抗体
WO2010091189A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
KR101686261B1 (ko) * 2009-03-11 2016-12-14 시오노기세야쿠 가부시키가이샤 항녹농균 작용을 갖는 인간화 ＰｃｒＶ 항체
CA2784033A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
KR102111171B1 (ko) * 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
KR102184343B1 (ko) 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
WO2013128031A1 (en) 2012-03-02 2013-09-06 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
MX2017014002A (es) * 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
ES2833773T3 (es) 2015-07-16 2021-06-15 Inhibrx Inc Proteínas de fusión que se unen a DR5 multivalentes y multiespecíficas
CA3023094A1 (en) 2016-05-05 2017-11-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
MX2021001305A (es) 2018-08-01 2021-06-23 Cephalon Inc Anticuerpos anti-cxcr2 y usos de los mismos.
KR20220019755A (ko) * 2019-06-11 2022-02-17 리제너론 파마슈티칼스 인코포레이티드 PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225552A (en) * 1880-03-16 Disintegrating-mill
US108565A (en) * 1870-10-25 Improvement in snow-plows
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
DE69726003T2 (de) 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
DK1049488T3 (da) * 1998-11-25 2006-06-26 Mcw Res Found Inc Fremgangsmåde og præparat til immunisering med Pseudomonas aeruginosa-V-antigenet
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
WO2001064749A2 (en) 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE60216564T2 (de) 2001-01-26 2007-10-11 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1479695B1 (en) * 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
DK2343380T3 (da) 2004-11-16 2019-09-09 Humanigen Inc Immunoglobulin variabel region kassetteudskiftning
US20090215165A1 (en) 2005-05-20 2009-08-27 James Rance High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
WO2007003010A1 (en) 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
PT2027156E (pt) 2006-06-02 2011-04-18 Aveo Pharmaceuticals Inc Proteínas de ligação ao factor de crescimento de hepatócito (hgf)
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof

Also Published As

Publication number Publication date
JP5781765B2 (ja) 2015-09-24
US20150030614A1 (en) 2015-01-29
JP2011505381A (ja) 2011-02-24
AU2008333985B2 (en) 2015-02-05
WO2009073631A3 (en) 2009-09-24
CN101910197B (zh) 2014-09-24
US8877191B2 (en) 2014-11-04
NZ586357A (en) 2012-10-26
ZA201003852B (en) 2014-11-26
MX2010005871A (es) 2010-06-09
US20090191186A1 (en) 2009-07-30
SG186017A1 (en) 2012-12-28
AU2008333985A1 (en) 2009-06-11
CN101910197A (zh) 2010-12-08
KR20100097719A (ko) 2010-09-03
IL206036A0 (en) 2010-11-30
US8044181B2 (en) 2011-10-25
WO2009073631A2 (en) 2009-06-11
US20120020986A1 (en) 2012-01-26
EP2220117A2 (en) 2010-08-25
BRPI0819598A2 (pt) 2017-05-09
CA2706732A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
NL301089I2 (nl) imlifidase
CY1122278T1 (el) Αντι il-36r αντισωματα
UA111818C2 (uk) Антитіло проти csf-1r
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
EA200970580A1 (ru) Таннат разагилина
WO2008115281A3 (en) Compounds for treating viral infections
MY177564A (en) Anti-nr10 antibody and use thereof
EA200701918A1 (ru) Белок липокалин
TW200626171A (en) Fixed dosing of HER antibodies
DK2164331T3 (da) Borholdige små molekyler
UA107791C2 (en) Pesticidal compositions
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов